 | • レポートコード：QYR9NV18397 • 出版社/出版日：QYResearch / 2019年11月18日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※当調査レポートでは、強皮症治療薬の世界市場について調査・分析し、強皮症治療薬の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（免疫抑制剤、ホスホジエステラーゼ5阻害剤-PHA、エンドセリン受容体拮抗薬、プロスタサイクリンアナログ、カルシウムチャネル遮断薬、鎮痛薬、その他）、用途別（全身、ローカライズ）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の強皮症治療薬市場動向 ・主要企業別マーケットシェア ・強皮症治療薬の種類別市場規模2014-2019 （免疫抑制剤、ホスホジエステラーゼ5阻害剤-PHA、エンドセリン受容体拮抗薬、プロスタサイクリンアナログ、カルシウムチャネル遮断薬、鎮痛薬、その他） ・強皮症治療薬の用途別市場規模2014-2019 （全身、ローカライズ） ・強皮症治療薬の北米市場：主要企業・種類別/用途別市場規模 ・強皮症治療薬のヨーロッパ市場：主要企業・種類別/用途別市場規模 ・強皮症治療薬の中国市場：主要企業・種類別/用途別市場規模 ・強皮症治療薬の日本国内市場：主要企業・種類別/用途別市場規模 ・強皮症治療薬の東南アジア市場：主要企業・種類別/用途別市場規模 ・強皮症治療薬のインド市場：主要企業・種類別/用途別市場規模 ・強皮症治療薬の中南米市場：主要企業・種類別/用途別市場規模 ・主要企業のプロフィール （F. Hoffmann-La Roche AG、Bristol-Myers Squibb Company、Celgene Corporation、Argentis Pharmaceuticals, LLC、Bayer AG、Boehringer Ingelheim International GmbH、Akashi Therapeutics、Prometic Life Sciences, Inc.、Emerald Health Pharmaceuticals、Kadmon Holdings, Inc.、Seattle Genetics, Inc.、Cytori Therapeutics, Inc.、Fibrocell Science, Inc.、Chemomab、Corbus Pharmaceuticals Holdings, Inc.、Genkyotex） ・強皮症治療薬の市場規模予測2019-2025 （種類別、用途別、地域別市場予測） ・アナリストの観点・結論 ... |
Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.The market is mainly driven by the off-label use of drugs approved for its symptomatic indications, such as rheumatoid arthritis.
In 2018, the global Scleroderma Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Scleroderma Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Scleroderma Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Celgene Corporation
Argentis Pharmaceuticals, LLC
Bayer AG
Boehringer Ingelheim International GmbH
Akashi Therapeutics
Prometic Life Sciences, Inc.
Emerald Health Pharmaceuticals
Kadmon Holdings, Inc.
Seattle Genetics, Inc.
Cytori Therapeutics, Inc.
Fibrocell Science, Inc.
Chemomab
Corbus Pharmaceuticals Holdings, Inc.
Genkyotex
Market segment by Type, the product can be split into
Immunosuppressors
Phosphodiesterase 5 Inhibitors – PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Analgesics
Others
Market segment by Application, split into
Systemic
Localized
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Scleroderma Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Scleroderma Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Scleroderma Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Scleroderma Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Immunosuppressors
1.4.3 Phosphodiesterase 5 Inhibitors – PHA
1.4.4 Endothelin Receptor Antagonists
1.4.5 Prostacyclin Analogues
1.4.6 Calcium Channel Blockers
1.4.7 Analgesics
1.4.8 Others
1.5 Market by Application
1.5.1 Global Scleroderma Therapeutics Market Share by Application (2019-2025)
1.5.2 Systemic
1.5.3 Localized
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Scleroderma Therapeutics Market Size
2.2 Scleroderma Therapeutics Growth Trends by Regions
2.2.1 Scleroderma Therapeutics Market Size by Regions (2019-2025)
2.2.2 Scleroderma Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
3 Market Share by Key Players
3.1 Scleroderma Therapeutics Market Size by by Players
3.1.1 Global Scleroderma Therapeutics Revenue by by Players (2014-2019)
3.1.2 Global Scleroderma Therapeutics Revenue Market Share by by Players (2014-2019)
3.1.3 Global Scleroderma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Scleroderma Therapeutics Key Players Head office and Area Served
3.3 Key Players Scleroderma Therapeutics Product/Solution/Service
3.4 Date of Enter into Scleroderma Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Scleroderma Therapeutics Market Size by Type (2014-2019)
4.2 Global Scleroderma Therapeutics Market Size by Application (2014-2019)
5 North America
5.1 North America Scleroderma Therapeutics Market Size (2014-2019)
5.2 Scleroderma Therapeutics Key Players in North America
5.3 North America Scleroderma Therapeutics Market Size by Type
5.4 North America Scleroderma Therapeutics Market Size by Application
6 Europe
6.1 Europe Scleroderma Therapeutics Market Size (2014-2019)
6.2 Scleroderma Therapeutics Key Players in Europe
6.3 Europe Scleroderma Therapeutics Market Size by Type
6.4 Europe Scleroderma Therapeutics Market Size by Application
7 China
7.1 China Scleroderma Therapeutics Market Size (2014-2019)
7.2 Scleroderma Therapeutics Key Players in China
7.3 China Scleroderma Therapeutics Market Size by Type
7.4 China Scleroderma Therapeutics Market Size by Application
8 Japan
8.1 Japan Scleroderma Therapeutics Market Size (2014-2019)
8.2 Scleroderma Therapeutics Key Players in Japan
8.3 Japan Scleroderma Therapeutics Market Size by Type
8.4 Japan Scleroderma Therapeutics Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Scleroderma Therapeutics Market Size (2014-2019)
9.2 Scleroderma Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Scleroderma Therapeutics Market Size by Type
9.4 Southeast Asia Scleroderma Therapeutics Market Size by Application
10 India
10.1 India Scleroderma Therapeutics Market Size (2014-2019)
10.2 Scleroderma Therapeutics Key Players in India
10.3 India Scleroderma Therapeutics Market Size by Type
10.4 India Scleroderma Therapeutics Market Size by Application
11 Central & South America
11.1 Central & South America Scleroderma Therapeutics Market Size (2014-2019)
11.2 Scleroderma Therapeutics Key Players in Central & South America
11.3 Central & South America Scleroderma Therapeutics Market Size by Type
11.4 Central & South America Scleroderma Therapeutics Market Size by Application
12 International Players Profiles
12.1 F. Hoffmann-La Roche AG
12.1.1 F. Hoffmann-La Roche AG Company Details
12.1.2 Company Description and Business Overview
12.1.3 Scleroderma Therapeutics Introduction
12.1.4 F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2014-2019))
12.1.5 F. Hoffmann-La Roche AG Recent Development
12.2 Bristol-Myers Squibb Company
12.2.1 Bristol-Myers Squibb Company Company Details
12.2.2 Company Description and Business Overview
12.2.3 Scleroderma Therapeutics Introduction
12.2.4 Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2014-2019)
12.2.5 Bristol-Myers Squibb Company Recent Development
12.3 Celgene Corporation
12.3.1 Celgene Corporation Company Details
12.3.2 Company Description and Business Overview
12.3.3 Scleroderma Therapeutics Introduction
12.3.4 Celgene Corporation Revenue in Scleroderma Therapeutics Business (2014-2019)
12.3.5 Celgene Corporation Recent Development
12.4 Argentis Pharmaceuticals, LLC
12.4.1 Argentis Pharmaceuticals, LLC Company Details
12.4.2 Company Description and Business Overview
12.4.3 Scleroderma Therapeutics Introduction
12.4.4 Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2014-2019)
12.4.5 Argentis Pharmaceuticals, LLC Recent Development
12.5 Bayer AG
12.5.1 Bayer AG Company Details
12.5.2 Company Description and Business Overview
12.5.3 Scleroderma Therapeutics Introduction
12.5.4 Bayer AG Revenue in Scleroderma Therapeutics Business (2014-2019)
12.5.5 Bayer AG Recent Development
12.6 Boehringer Ingelheim International GmbH
12.6.1 Boehringer Ingelheim International GmbH Company Details
12.6.2 Company Description and Business Overview
12.6.3 Scleroderma Therapeutics Introduction
12.6.4 Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2014-2019)
12.6.5 Boehringer Ingelheim International GmbH Recent Development
12.7 Akashi Therapeutics
12.7.1 Akashi Therapeutics Company Details
12.7.2 Company Description and Business Overview
12.7.3 Scleroderma Therapeutics Introduction
12.7.4 Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2014-2019)
12.7.5 Akashi Therapeutics Recent Development
12.8 Prometic Life Sciences, Inc.
12.8.1 Prometic Life Sciences, Inc. Company Details
12.8.2 Company Description and Business Overview
12.8.3 Scleroderma Therapeutics Introduction
12.8.4 Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2014-2019)
12.8.5 Prometic Life Sciences, Inc. Recent Development
12.9 Emerald Health Pharmaceuticals
12.9.1 Emerald Health Pharmaceuticals Company Details
12.9.2 Company Description and Business Overview
12.9.3 Scleroderma Therapeutics Introduction
12.9.4 Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2014-2019)
12.9.5 Emerald Health Pharmaceuticals Recent Development
12.10 Kadmon Holdings, Inc.
12.10.1 Kadmon Holdings, Inc. Company Details
12.10.2 Company Description and Business Overview
12.10.3 Scleroderma Therapeutics Introduction
12.10.4 Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2014-2019)
12.10.5 Kadmon Holdings, Inc. Recent Development
12.11 Seattle Genetics, Inc.
12.12 Cytori Therapeutics, Inc.
12.13 Fibrocell Science, Inc.
12.14 Chemomab
12.15 Corbus Pharmaceuticals Holdings, Inc.
12.16 Genkyotex
13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
Table Scleroderma Therapeutics Key Market Segments
Table Key Players Scleroderma Therapeutics Covered
Table Global Scleroderma Therapeutics Market Size Growth Rate by Type 2018-2025 (Million US$)
Figuer Immunosuppressors Figures
Table Key Players of Immunosuppressors
Figuer Phosphodiesterase 5 Inhibitors - PHA Figures
Table Key Players of Phosphodiesterase 5 Inhibitors - PHA
Figuer Endothelin Receptor Antagonists Figures
Table Key Players of Endothelin Receptor Antagonists
Figuer Prostacyclin Analogues Figures
Table Key Players of Prostacyclin Analogues
Figuer Calcium Channel Blockers Figures
Table Key Players of Calcium Channel Blockers
Figuer Analgesics Figures
Table Key Players of Analgesics
Figuer Others Figures
Table Key Players of Others
Table Global Scleroderma Therapeutics Market Size Growth by Application 2019-2025 (Million US$)
Figure Global Scleroderma Therapeutics Market Share by Application in 2018 & 2025
Figure Systemic Case Studies
Figure Localized Case Studies
Figure Scleroderma Therapeutics Report Years Considered
Figure Global Scleroderma Therapeutics Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Scleroderma Therapeutics Market Size by Regions 2019-2025 (Million US$)
Table Global Scleroderma Therapeutics Market Size by Regions 2019-2025 (Million US$)
Table Global Scleroderma Therapeutics Market Share by Regions 2014-2019
Figure Global Scleroderma Therapeutics Market Share by Regions 2014-2019
Figure Global Scleroderma Therapeutics Market Share by Regions in 2018
Table Market Top Trends
Table Key Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Figure PORTER'S FIVE FORCES ANALYSIS
Table Global Scleroderma Therapeutics Revenue by by Players (2014-2019) (Million US$)
Table Global Scleroderma Therapeutics Market Share by by Players (2014-2019)
Figure Global Scleroderma Therapeutics Market Share by by Players in 2018
Table Global Scleroderma Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Scleroderma Therapeutics Product/Solution/Service
Table Date of Enter into Scleroderma Therapeutics Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Scleroderma Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Global Scleroderma Therapeutics Market Size Share by Type (2014-2019)
Figure Global Scleroderma Therapeutics Market Size Market Share by Type (2014-2019)
Table Global Scleroderma Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Global Scleroderma Therapeutics Market Size Share by Application (2014-2019)
Figure Global Scleroderma Therapeutics Market Size Market Share by Application (2014-2019)
Figure Global Scleroderma Therapeutics Revenue Market Share by Application in 2018
Figure North America Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table North America Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table North America Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table North America Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table North America Scleroderma Therapeutics Market Share by Type 2014-2019
Table North America Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table North America Scleroderma Therapeutics Market Share by Application 2014-2019
Figure Europe Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table Europe Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table Europe Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table Europe Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Europe Scleroderma Therapeutics Market Share by Type 2014-2019
Table Europe Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Europe Scleroderma Therapeutics Market Share by Application 2014-2019
Figure China Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table China Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table China Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table China Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table China Scleroderma Therapeutics Market Share by Type 2014-2019
Table China Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table China Scleroderma Therapeutics Market Share by Application 2014-2019
Figure Japan Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table Japan Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table Japan Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table Japan Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Japan Scleroderma Therapeutics Market Share by Type 2014-2019
Table Japan Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Japan Scleroderma Therapeutics Market Share by Application 2014-2019
Figure Southeast Asia Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table Southeast Asia Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Southeast Asia Scleroderma Therapeutics Market Share by Type 2014-2019
Table Southeast Asia Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Southeast Asia Scleroderma Therapeutics Market Share by Application 2014-2019
Figure India Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table India Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table India Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table India Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table India Scleroderma Therapeutics Market Share by Type 2014-2019
Table India Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table India Scleroderma Therapeutics Market Share by Application 2014-2019
Figure Central & South America Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table Central & South America Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Central & South America Scleroderma Therapeutics Market Share by Type 2014-2019
Table Central & South America Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Central & South America Scleroderma Therapeutics Market Share by Application 2014-2019
Table F. Hoffmann-La Roche AG Company Details
Table F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure F. Hoffmann-La Roche AG Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table F. Hoffmann-La Roche AG Recent Development
Table Bristol-Myers Squibb Company Company Details
Table Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Bristol-Myers Squibb Company Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Bristol-Myers Squibb Company Recent Development
Table Celgene Corporation Company Details
Table Celgene Corporation Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Celgene Corporation Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Celgene Corporation Recent Development
Table Argentis Pharmaceuticals, LLC Company Details
Table Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Argentis Pharmaceuticals, LLC Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Argentis Pharmaceuticals, LLC Recent Development
Table Bayer AG Company Details
Table Bayer AG Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Bayer AG Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Bayer AG Recent Development
Table Boehringer Ingelheim International GmbH Company Details
Table Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Boehringer Ingelheim International GmbH Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Boehringer Ingelheim International GmbH Recent Development
Table Akashi Therapeutics Company Details
Table Akashi Therapeutics Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Akashi Therapeutics Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Akashi Therapeutics Recent Development
Table Prometic Life Sciences, Inc. Company Details
Table Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Prometic Life Sciences, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Prometic Life Sciences, Inc. Recent Development
Table Emerald Health Pharmaceuticals Company Details
Table Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Emerald Health Pharmaceuticals Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Emerald Health Pharmaceuticals Recent Development
Table Kadmon Holdings, Inc. Company Details
Table Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Kadmon Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Kadmon Holdings, Inc. Recent Development
Table Seattle Genetics, Inc. Company Details
Table Cytori Therapeutics, Inc. Company Details
Table Fibrocell Science, Inc. Company Details
Table Chemomab Company Details
Table Corbus Pharmaceuticals Holdings, Inc. Company Details
Table Genkyotex Company Details
Table Global Scleroderma Therapeutics Market Size by Regions (Million US$) 2019-2025
Figure Global Scleroderma Therapeutics Market Size Share by Regions (2019-2025)
Figure Global Scleroderma Therapeutics Market Size Share by Regions in 2025
Figure North America Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Europe Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure China Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Japan Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure India Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Table Global Scleroderma Therapeutics Market Size by Product (2019-2025) (Million US$)
Figure Global Scleroderma Therapeutics Market Size by Product (2019-2025)
Figure Global Scleroderma Therapeutics Market Size by Product in 2025
Table Global Scleroderma Therapeutics Market Size by Application (2019-2025) (Million US$)
Figure Global Scleroderma Therapeutics Market Size by Application (2019-2025)
Figure Global Scleroderma Therapeutics Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
強皮症治療薬のグローバル市場：規模・現状・予測2019-2025 Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.The m…- 強皮症の診断および治療のグローバル市場調査 2019年 The global Scleroderma Diagnostics and Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Scleroderma Diagnostics and Therapeutics volume and value at global level, regional level and comp…
- 強皮症の診断および治療のグローバル市場調査 2019年 The global Scleroderma Diagnostics and Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Scleroderma Diagnostics and Therapeutics volume and value at global level, regional level and comp…
- 冠動脈疾患治療薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Coronary artery disease (CAD), also known as ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. Scope of the Report: This report studies the Coronary Artery Disease Therapeutics market status and…
- 世界のホスホジエステラーゼ（PDE）阻害剤産業調査2019-2025 A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE…